Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.

Front Immunol · 2023 · PMC10331819 · PMID 37435087

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

barely significantlyno p-value reported

Compared with placebo, serplulimab (HR = 2.67, 95% CI: 1.27 to 5.62) barely significantly increased the 5th month PFS rate.

also in 36 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.